Abstract
Evidence regarding long-acting beta-agonist safety and specific step up and step down recommendations in children that have been published since the National Asthma Education Prevention Program Guidelines for the Diagnosis and Management Expert Panel Report 3 are reviewed. Despite several systematic reviews involving many thousands of patients, the safety of long-acting beta-agonists in children remains under debate. Although the role of inhaled corticosteroids has been well established in children, whether the ideal add on therapy should be a long-acting betaagonist or a leukotriene receptor antagonist, balancing efficacy with safety information, remains controversial. The ideal step down regimen to be used after asthma control has been achieved is similarly not well established. Additional research in children is needed to answer these questions, particularly in the youngest age groups.
Keywords: Asthma, guidelines, leukotriene receptor antagonists, long-acting beta-agonists, pediatric, pharmacotherapy
Current Pediatric Reviews
Title: Adjusting Controller Medications in Children: Evidence for Step Up and Down Choices after EPR-3
Volume: 8 Issue: 1
Author(s): Mona G. Tsoukleris, Donna Huynh and Jill A. Morgan
Affiliation:
Keywords: Asthma, guidelines, leukotriene receptor antagonists, long-acting beta-agonists, pediatric, pharmacotherapy
Abstract: Evidence regarding long-acting beta-agonist safety and specific step up and step down recommendations in children that have been published since the National Asthma Education Prevention Program Guidelines for the Diagnosis and Management Expert Panel Report 3 are reviewed. Despite several systematic reviews involving many thousands of patients, the safety of long-acting beta-agonists in children remains under debate. Although the role of inhaled corticosteroids has been well established in children, whether the ideal add on therapy should be a long-acting betaagonist or a leukotriene receptor antagonist, balancing efficacy with safety information, remains controversial. The ideal step down regimen to be used after asthma control has been achieved is similarly not well established. Additional research in children is needed to answer these questions, particularly in the youngest age groups.
Export Options
About this article
Cite this article as:
G. Tsoukleris Mona, Huynh Donna and A. Morgan Jill, Adjusting Controller Medications in Children: Evidence for Step Up and Down Choices after EPR-3, Current Pediatric Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339612799746281
DOI https://dx.doi.org/10.2174/157339612799746281 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamin D Supplementation in Diabetic Foot Ulcers: A Current Perspective
Current Diabetes Reviews Quality of Life Questionnaires for Children With Bronchial Asthma at Jordan University Hospital: An Observational Study
Current Respiratory Medicine Reviews Supercritical Fluid Particle Design for Poorly Water-soluble Drugs (Review)
Current Pharmaceutical Design The Role of Inspiratory Pressures in Determining the Flow Rates Though Dry Powder Inhalers; A Review
Current Pharmaceutical Design Therapeutic Potential of Galectin-1 and Galectin-3 in Autoimmune Diseases
Current Pharmaceutical Design Immunomodulatory Treatment Strategies for Allergic Diseases
Current Drug Targets - Inflammation & Allergy Pharmaceuticals and Cosmeceuticals Based on Soft Nanotechnology Techniques with Antioxidative, Immunostimulative and other Therapeutic Activities
Recent Patents on Nanotechnology Pharmacological Approaches in an Experimental Model of Non-Small Cell Lung Cancer: Effects on Tumor Biology
Current Pharmaceutical Design Anti-Inflammatory and Anti-Oxidant Activity of a New Class of Phenyl- Pyrazolone Derivatives
Current Drug Discovery Technologies Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Polymeric Drug Delivery Approaches for Colon Targeting: A Review
Drug Delivery Letters Transdermal Buprenorphine-A Novel Medication for Postoperative Pain Management Following Abdominal Hysterectomy for Benign Gynecological Conditions
Current Women`s Health Reviews Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases
Current Pharmaceutical Design Eicosanoids in Prevention and Management of Diseases
Current Molecular Medicine DNA Methylation Markers in Lung Cancer
Current Genomics Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Correlations between the Youth Healthy Eating Index, Body Mass Index and the Salivary Nitric Oxide Concentration in Overweight/Obese Children
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease
Current Medicinal Chemistry Aspartate and Glutamate Mimetic Structures in Biologically Active Compounds
Current Medicinal Chemistry Antidiabetic Oils
Current Diabetes Reviews